ARA-290
RecoveryPreclinicalAlso known as: Cibinetide
ARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production. With a molecular weight of 1257 Da, ARA-290 was developed as a deliberate pharmaceutical engineering attempt to separate the tissue-protective and anti-inflammatory effects of EPO from its hematopoietic effects — producing a drug that could deliver the neuroprotective and healing properties of EPO without the clot risk, blood pressure elevation, and policing concerns that surround recombinant EPO use (Brines et al., 2008). The scientific story behind ARA-290 is unusual and worth understanding.
Overview
At A Glance
ARA-290's mechanism of action is one of the more elegantly engineered examples of pharmaceutical design in the peptide space. Understanding it requires appreciation of the dual-receptor biology of erythropoietin and the specific receptor-selective engineering that created ARA-290…
Mechanism of Action
ARA-290's mechanism of action is one of the more elegantly engineered examples of pharmaceutical design in the peptide space. Understanding it requires appreciation of the dual-receptor biology of erythropoietin and the specific receptor-selective engineering that created ARA-290.
The dual-receptor biology of EPO. Erythropoietin has two distinct receptor targets with different biology. The classical EPO receptor (EPOR) exists as a homodimer (EPOR/EPOR) on bone marrow erythroid progenitor cells. When EPO binds this homodimer, it activates JAK2 kinase and STAT5 transcription factor, driving erythroid cell proliferation, survival, and differentiation — the hematopoietic effect that produces red blood cells. This homodimer has high binding affinity for EPO (Kd approximately 0.1 nM) and is the target of recombinant EPO (epoetin alfa, darbepoetin) in the treatment of renal anemia and chemotherapy-induced anemia.
However, EPO also binds a distinct heteromeric receptor complex — the innate repair receptor (IRR) — consisting of EPOR + beta-common receptor (βcR, also called CD131). This heteromer is expressed on a variety of tissues: neurons, Schwann cells, cardiomyocytes, vascular endothelium, retinal photoreceptors, renal tubular cells, skin fibroblasts, and immune cells. Binding of EPO to the IRR activates JAK2/STAT3, MAPK, and PI3K/Akt pathways, driving anti-inflammatory, anti-apoptotic, pro-regenerative, and neuroprotective effects. The IRR has LOWER affinity for EPO than the hematopoietic homodimer (Kd approximately 1-10 nM), meaning IRR-mediated effects require higher EPO concentrations than hematopoietic effects at equilibrium (Brines & Cerami, 2012).
The engineering rationale for ARA-290. The problem with using recombinant EPO for tissue protection is that the doses needed to activate the lower-affinity IRR also robustly activate the hematopoietic receptor, producing unwanted polycythemia, elevated blood pressure, and thrombotic risk. This became especially concerning when large clinical trials of recombinant EPO in non-anemia contexts (stroke, acute kidney injury) showed signals of worsened mortality despite tissue-protective mechanism. The solution was to design a peptide that would selectively activate the IRR without engaging the hematopoietic homodimer.
The ARA-290 sequence QEQLERALNSS corresponds to a region on the external surface of helix B of EPO — a domain predicted by crystal structure analysis to make critical contacts with the beta-common receptor component of the IRR but not with the classical EPO receptor binding interface. When this 11-amino-acid peptide is administered, it binds the beta-common receptor and stabilizes the IRR heteromer, triggering its downstream signaling. Crucially, ARA-290 does not bind the classical EPO receptor homodimer effectively — so it does not produce erythropoiesis, does not elevate hematocrit, and does not carry the thrombotic risks of EPO (Brines et al., 2008).
Downstream signaling effects. IRR activation by ARA-290 triggers multiple beneficial downstream cascades:
JAK2/STAT3 signaling: Activates anti-apoptotic programs (BCL-2, BCL-xL upregulation), pro-survival gene expression, and anti-inflammatory signaling (IL-10 upregulation, SOCS3 induction).
MAPK (ERK, p38) signaling: Supports cell proliferation, tissue regeneration, and controlled inflammatory resolution.
PI3K/Akt signaling: Anti-apoptotic, metabolic regulation, and cell survival promotion.
NF-kB modulation: Reduces pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta) through interference with NF-kB signaling pathways.
Anti-inflammatory mechanism. ARA-290 reduces production of multiple pro-inflammatory cytokines and supports resolution of inflammation through:
- Decreased TNF-alpha, IL-6, IL-1beta, and IL-8 from activated immune cells
- Increased IL-10 (anti-inflammatory cytokine) production
- Modulation of macrophage polarization from pro-inflammatory M1 phenotype toward resolving M2 phenotype
- Reduction of neutrophil infiltration and activation in tissue injury
- Preservation of regulatory T-cell populations
This anti-inflammatory signature is qualitatively similar to what other tissue-protective peptides produce (like KPV or BPC-157) but mediated through a distinct receptor pathway.
Neuroprotection and nerve fiber regeneration. In neurological tissue, IRR activation promotes:
- Neuronal survival under ischemic or metabolic stress
- Schwann cell function and myelin maintenance
- Axonal regeneration in damaged peripheral nerves
- Increased intraepidermal nerve fiber density (measurable on skin biopsy in clinical trials)
- Reduced microglial pro-inflammatory activation
- Mitochondrial protection in neurons
These combined effects explain ARA-290's observed benefits in small fiber neuropathy models and clinical trials (Swartjes et al., 2014).
Microvascular and endothelial effects. The IRR is expressed on vascular endothelium, and ARA-290 has documented effects on microvascular perfusion:
- Improved endothelial nitric oxide synthase activity
- Modest vasodilatation in capillary beds
- Reduced endothelial pro-inflammatory cytokine expression
- Improved tissue perfusion in models of diabetic microvascular dysfunction
This mechanism contributes to ARA-290's activity in diabetic complication models where microvascular dysfunction is central.
Wound healing and tissue repair mechanisms. In models of dermal wound healing, ischemia-reperfusion injury, and burn injury, ARA-290 accelerates healing through:
- Reduced inflammatory cell infiltration
- Accelerated granulation tissue formation
- Enhanced re-epithelialization
- Reduced fibrosis compared to untreated wounds
- Supported angiogenesis for tissue reperfusion
These effects overlap mechanistically (though through different receptors) with the healing effects seen with BPC-157, TB-500, and GHK-Cu.
Cardiac protection mechanisms. In myocardial ischemia-reperfusion models, ARA-290 reduces infarct size, improves functional recovery, and reduces apoptotic cell death in myocardium. These effects are IRR-mediated and distinguishable from effects that would require hematopoietic EPO receptor activation.
What ARA-290 does NOT do (selectivity profile).
No hematopoiesis: At clinically-studied doses, ARA-290 does not increase hematocrit, red blood cell count, or reticulocyte count. This is the primary engineering goal and has been confirmed in clinical trials — no polycythemia with ARA-290 at therapeutic doses, even with chronic administration.
No thrombotic risk signal: Because hematocrit remains unchanged and vascular function is generally improved (not impaired as with EPO-induced hypertension), thrombotic risk does not appear elevated with ARA-290.
No hypertension: Unlike recombinant EPO which can raise blood pressure substantially (part of the hematocrit-related mechanism), ARA-290 does not affect blood pressure meaningfully in trials.
Limited hematopoietic effects at any dose: The selectivity is quite clean — doses that produce strong tissue-protective effects do not affect erythropoiesis. This is in contrast to some failed attempts at separation (carbamoylated EPO, asialo-EPO) that retained some hematopoietic activity.
Pharmacokinetics. ARA-290 has a short plasma half-life (minutes to tens of minutes) after subcutaneous administration, which is typical for small peptides cleared by peptidases and renal filtration. Despite the short plasma half-life, biological effects are durable — lasting hours to days — because the downstream effects on gene expression and tissue signaling persist after peptide clearance. This is a pattern seen with many tissue-protective peptides where the active compound initiates a signaling cascade that outlasts its own presence.
Differences from full recombinant EPO. The key differences between ARA-290 and recombinant EPO in terms of mechanism:
- Receptor selectivity: ARA-290 only activates IRR; EPO activates both IRR and hematopoietic receptor
- Size: 1257 Da vs ~30,000 Da for EPO
- Immunogenicity: Small peptide less immunogenic than large glycoprotein
- Manufacturing: Chemical peptide synthesis vs recombinant production
- Dose range: Tissue-protective at 4 mg SubQ daily (ARA-290) vs requiring much higher EPO doses for equivalent effects
Interactions with other peptide mechanisms. ARA-290's IRR-mediated anti-inflammatory and regenerative effects are complementary to other mechanism categories:
- BPC-157 (growth hormone receptor, NO pathway)
- TB-500 (actin sequestration, cell migration)
- GHK-Cu (copper-peptide signaling, wound healing)
- KPV (PepT1-mediated NF-kB inhibition)
- Thymosin Alpha-1 (immune modulation)
These mechanisms are non-overlapping, making stack combinations theoretically additive.
Overview
ARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production. With a molecular weight of 1257 Da, ARA-290 was developed as a deliberate pharmaceutical engineering attempt to separate the tissue-protective and anti-inflammatory effects of EPO from its hematopoietic effects — producing a drug that could deliver the neuroprotective and healing properties of EPO without the clot risk, blood pressure elevation, and policing concerns that surround recombinant EPO use (Brines et al., 2008).
The scientific story behind ARA-290 is unusual and worth understanding. Erythropoietin is best known as the kidney hormone that stimulates bone marrow to make red blood cells. But researchers noted in the early 2000s that recombinant EPO had unexpected protective effects in tissue injury models far removed from anemia — it reduced damage after stroke, reduced damage after heart attack, accelerated wound healing, reduced neuropathic pain, and dampened inflammation. These effects were too broad and too strong to be coincidence. The team led by Michael Brines and Anthony Cerami proposed and eventually confirmed that EPO has two distinct receptor targets: the classical EPO receptor homodimer (EPOR/EPOR) on bone marrow cells, which drives hematopoiesis, and a heteromeric "innate repair receptor" (IRR) consisting of EPOR + beta-common receptor, expressed on tissues like nerves, heart, brain, skin, and retina, which drives tissue protection and anti-inflammatory effects (Brines & Cerami, 2012).
The engineering achievement with ARA-290 was to design a peptide that selectively activates the IRR without triggering the hematopoietic EPO receptor. The parent 11-amino-acid sequence was derived from the external surface of helix B of EPO — a region predicted to interact with the beta-common receptor component of the IRR. The engineered peptide binds the IRR and triggers its tissue-protective downstream signaling (JAK2/STAT3/STAT5, MAPK, Akt pathways) but does not meaningfully activate erythropoiesis. This means ARA-290 can be given at doses that produce strong anti-inflammatory and tissue-protective effects without raising hematocrit, increasing thrombosis risk, or producing hypertension — the primary safety concerns of EPO in non-anemia contexts.
ARA-290's clinical development has focused primarily on neuropathic pain, especially small fiber neuropathy — a type of neuropathy involving damage to small unmyelinated C-fibers and thinly myelinated A-delta fibers, causing burning pain, allodynia, and autonomic symptoms. Small fiber neuropathy is common in diabetes, sarcoidosis, idiopathic etiologies, and several immune-mediated conditions. It is often refractory to conventional neuropathic pain drugs (gabapentin, pregabalin, duloxetine, tricyclic antidepressants). Multiple Phase 2 trials in sarcoidosis-associated small fiber neuropathy have shown ARA-290 significantly reduces pain scores and improves quality of life measures over 4-12 weeks of daily subcutaneous administration at 4 mg doses (Culver et al., 2017, Dahan et al., 2013).
The mechanism in neuropathic pain involves tissue-level effects on inflammation, nerve fiber integrity, and small blood vessel function. ARA-290 reduces pro-inflammatory cytokine production, supports nerve fiber regeneration (measurable as increased intraepidermal nerve fiber density on skin biopsy in some trials), and modulates microvascular perfusion to nerves. The effects develop gradually over weeks of treatment, consistent with tissue-level healing rather than immediate analgesia. This gradual onset distinguishes ARA-290 from conventional neuropathic pain medications that work through ion channel modulation (Heij et al., 2012).
Beyond sarcoidosis-associated neuropathy, ARA-290 has been studied in diabetic neuropathy, chemotherapy-induced neuropathy, neuropathic pain from other causes, and exploratory applications in inflammatory conditions. The pharmaceutical development has proceeded through Araim Pharmaceuticals, with ARA-290 (cibinetide) progressing through various phases of clinical trials. As of early 2026, ARA-290 is NOT FDA-approved as a drug — it exists as an investigational compound and research peptide. Availability in the community has come through research peptide suppliers rather than pharmaceutical channels, which introduces quality control and sourcing considerations that are not present with approved medications.
The research peptide community has taken interest in ARA-290 primarily for three reasons. First, the mechanism — innate repair receptor activation with tissue-protective and anti-inflammatory signaling — is conceptually attractive for recovery, injury healing, and general "anti-aging" or "regenerative" applications. Second, the clinical evidence for neuropathic pain is more solid than for many research peptides, with multiple Phase 2 studies published in peer-reviewed journals. Third, the safety profile in clinical trials has been favorable — no thrombotic events, no hypertension, no elevated hematocrit, in line with the rational design goal of separating tissue protection from hematopoietic effects (Brines et al., 2015).
The community uses of ARA-290 extend beyond the clinically-studied neuropathic pain indications. Common use patterns include: general tissue repair and anti-inflammatory support, adjunct therapy for chronic inflammation, recovery from injuries (soft tissue, post-surgical), diabetic complication support beyond neuropathy, exercise-related inflammation, autoimmune adjunct therapy, and experimental applications in various chronic conditions. Evidence for these community uses is sparse to nonexistent — they represent extrapolation from mechanism and from the neuropathic pain trial data rather than from direct clinical evidence.
The honest framing for anyone considering ARA-290: the pharmacology is sophisticated and the clinical trial evidence for small fiber neuropathy (particularly sarcoidosis-associated) is among the better-supported applications in the research peptide space. Outside of that specific indication, use is mechanism-based and speculative. The safety profile in trials has been reassuring, but trial populations are limited and long-term safety data beyond months of use are sparse. It is NOT FDA-approved, and community use requires the caveats that accompany any research peptide: sourcing quality, injection technique, understanding that you are using a drug not yet approved for marketing, and acknowledgment that the evidence base beyond neuropathic pain is thin. For a specific indication like sarcoidosis-associated small fiber neuropathy in a patient who has failed conventional therapy, ARA-290 is a defensible consideration. For general wellness or anti-aging use, the evidence base does not support the substantial cost and complexity.
Chemical Information
IUPAC Name
{[Tyr(SO3H)]-Cys-Glu-Gln-Ala-Tyr-Gln-Leu-Glu-Ala-Arg-Ala-Leu-Leu-Asp-Gln-Ala-Val-Arg-Gly-Gln}[(Cys-Cys)]
CAS Number
1002360-15-1
Molecular Formula
C65H92N18O16
Molecular Mass
1397.64 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction Matrix
Contraindications
ARA-290's favorable safety profile in clinical trials makes for a relatively limited contraindication list, but specific cautions apply.
Absolute contraindications:
Known hypersensitivity to ARA-290 or formulation excipients. Prior severe allergic reaction to ARA-290 or bacteriostatic water preservatives contraindicates repeat use.
Active malignancy without oncology coordination. Despite the different receptor selectivity compared to EPO, ARA-290 has tissue-protective and anti-apoptotic effects. In theory, this could affect tumor cell survival. Classical EPO has been restricted in oncology contexts due to concerns about potentially promoting tumor survival. Whether ARA-290's IRR selectivity eliminates this concern is not fully established. For patients with active cancer or recent (<5 year) cancer history, ARA-290 should not be used without explicit oncology clearance and coordination.
Untreated serious active infection. ARA-290 has immunomodulatory and anti-inflammatory effects. During active sepsis, serious bacterial infection, or disseminated viral infection, blunting inflammatory response may be counterproductive. Treat infection first; consider ARA-290 after resolution.
Relative contraindications (caution required):
Pregnancy. No human safety data. ARA-290 should be avoided during pregnancy absent specific clinical indication and obstetrical oversight. The theoretical tissue-protective effects might be hypothetically beneficial, but without data, caution is appropriate.
Lactation. Similar lack of data. Avoid during breastfeeding.
Active or recent (< 6 months) thrombotic event. Though clinical trials have not shown thrombotic events with ARA-290 (unlike recombinant EPO), patients with recent DVT, PE, stroke, or MI should use ARA-290 with caution and physician oversight.
Significant cardiovascular disease. While ARA-290 has shown cardiac-protective effects in preclinical studies, patients with unstable cardiovascular disease should coordinate use with cardiologist.
Uncontrolled hypertension. Although ARA-290 has not shown hypertensive effects in trials (unlike recombinant EPO), patients with poorly-controlled hypertension should establish blood pressure control before initiating.
Recent surgery. Allow wound healing to complete before starting injections. Typically 2-4 weeks post-surgery; more for major procedures. If planning elective surgery, stop ARA-290 7-14 days before procedure.
Severe kidney disease. No specific contraindication, but pharmacokinetics not studied in advanced renal disease. Coordinate with nephrology.
Severe liver disease. No specific contraindication, but coordinate with gastroenterology/hepatology.
Active immunosuppressive therapy. May compound anti-inflammatory effects with potential for infection risk. Coordinate with prescribing physician.
Drug interactions:
Recombinant EPO (epoetin, darbepoetin). No specific clinical data on combination. Mechanistically the rationale for ARA-290 is to avoid EPO's hematopoietic effects; combining them would seem to defeat that purpose. Not a typical clinical scenario.
Corticosteroids. Commonly used concurrently with ARA-290 in sarcoidosis trials without reported problems. No clinically significant interaction documented. Anti-inflammatory effects may be additive.
Methotrexate, cyclosporine, tacrolimus, mycophenolate. Used concurrently in some sarcoidosis trial patients. No specific interaction reported. Theoretical concern about additive immunomodulation; monitor for infection.
Anti-TNF biologics (infliximab, adalimumab, etanercept). Sarcoidosis trial patients have used these concurrently with ARA-290. No documented interaction. Monitor for infection as with any combined anti-inflammatory therapy.
Neuropathic pain medications (gabapentin, pregabalin, duloxetine, tricyclic antidepressants, opioid analgesics). No known clinically significant interaction. Different mechanisms. Combination may be additive or synergistic in neuropathic pain. Standard dose management of each.
Chemotherapy. Oncology coordination essential. Theoretical concerns about growth factor-related effects on tumor cells.
Anticoagulants, antiplatelets. No known interaction. ARA-290 does not affect coagulation pathways meaningfully.
Antiarrhythmic drugs. No known interaction. ARA-290 has not shown arrhythmogenic effects in trials.
Diabetes medications (insulin, metformin, sulfonylureas, GLP-1 agonists). No known interaction. Compatible. Note that ARA-290 may improve diabetic microvascular function, which could theoretically improve glycemic control over time; monitor as usual.
Statins. No known interaction.
Thyroid replacement. No known interaction.
Estrogen/hormone replacement therapy. No known interaction.
Growth hormone or GH secretagogues (CJC-1295, Ipamorelin, MK-677). No known interaction. Compatible.
Other research peptides (BPC-157, TB-500, GHK-Cu, KPV, Thymosin Alpha-1). Widely stacked in community. No reported significant interactions. Different mechanism targets.
Vaccines. No specific contraindication. Standard vaccine response should be adequate.
Alcohol. No direct interaction. Moderate alcohol consumption is not contraindicated.
Specific population considerations:
Athletes/sports contexts. ARA-290 is NOT prohibited by WADA or major sports authorities as a specific compound as of early 2026, but EPO-related compounds have historically faced scrutiny. Athletes in tested sports should verify current regulatory status. Given the anti-inflammatory and recovery-related effects, therapeutic use should be documented carefully.
Elderly. Adult dosing generally appropriate. Monitor for drug interactions (more common with polypharmacy). Specific geriatric data limited but extrapolation from trial populations (which have included older adults) is reasonable.
Pediatric. No pediatric data. Inappropriate for community use in children.
Sickle cell disease. No specific data. The distinct receptor mechanism suggests no exacerbation of sickling, but clinical experience is absent. Coordinate with hematology.
Polycythemia vera or secondary polycythemia. Reassuringly, ARA-290 does not stimulate erythropoiesis. Patients with these conditions should theoretically be safe, but coordinate with hematology to monitor hematocrit during treatment.
Inherited prothrombotic disorders (Factor V Leiden, prothrombin mutation, etc.). Not specifically studied. Standard trial populations may not have specifically included these patients. Coordinate with hematology if these conditions are present.
Genetic considerations.
EPO receptor polymorphisms. Some variants affect EPO responsiveness. Whether these affect ARA-290 responsiveness is less clear; the receptor selectivity of ARA-290 may reduce variability.
Beta-common receptor variants. Potentially relevant for ARA-290 response. Not routinely tested.
Monitoring recommendations.
Baseline:
- CBC with differential (hematocrit, hemoglobin — to confirm no polycythemia during treatment)
- Comprehensive metabolic panel
- Blood pressure
- Condition-specific evaluation
Periodic (every 4-8 weeks during treatment):
- CBC (confirm stable hematocrit)
- CMP
- Blood pressure
- Condition response assessment
Extended use monitoring:
- At 6 months: Expanded panel, reassessment of ongoing benefit
- Annually: Comprehensive re-evaluation
Stop ARA-290 and seek medical evaluation for:
- Unexpected significant increase in hematocrit or hemoglobin
- Unexpected hypertension or blood pressure instability
- Signs of thrombotic event (leg pain/swelling, chest pain, shortness of breath, neurologic symptoms)
- Allergic reaction signs
- New infection symptoms
- Any severe or progressive symptom
- Pregnancy discovery
- New cancer diagnosis
Not contraindications (common misconceptions):
- Mild to moderate hypertension (if controlled)
- Type 2 diabetes (actually may be indication)
- Stable cardiovascular disease (may be beneficial)
- Previous uncomplicated surgery (after healing)
- History of seasonal allergies
- Normal infection history
- Most standard medications
Pre-ARA-290 decision checklist.
Before starting ARA-290, confirm:
- Specific indication with at least moderate evidence basis (sarcoidosis-SFN, diabetic neuropathy, etc.)
- Absence of absolute contraindications
- Awareness of relative contraindications and appropriate clinical oversight
- Informed consent regarding investigational status
- Reliable source with valid COA
- Financial sustainability for treatment course
- Logistical ability for daily injections
- Monitoring plan in place
When to include physician oversight.
Strongly consider physician involvement if:
- Any of the relative contraindications apply
- On multiple medications (even if no specific documented interaction)
- Advanced age or polypharmacy
- Complex medical history
- Specific condition with evidence base (sarcoidosis, diabetic neuropathy) — clinician familiar with condition
- Using for indication outside clinical trial evidence
- Intending prolonged use (6+ months)
- Stacking with multiple other peptides
Final framing.
ARA-290's safety profile in clinical trials has been notably clean. Most users tolerate it well. The short list of contraindications reflects this — it's a relatively low-interaction, low-side-effect compound when used appropriately. That said, it's an investigational drug not FDA-approved for any indication, so the standard cautions about peptide sourcing, preparation, and informed consent apply to any community use.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$49.99
up to $179.00
$3.5800
2
4
vial
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
ARA-290 10mg | vial | 1 vial● Out of Stock | $59.00BEST | $5.900 | — | Sign in for stock alert |
|
|
ARA-290 16mg | vial | 1 vial● Out of Stock | $75.00 | $4.688 | — | Sign in for stock alert |
|
|
ARA-290 50mg | vial | 1 vial● Out of Stock | $179.00VALUE | $3.580 | — | Sign in for stock alert |
 |
ARA-290 10mg | vial | 1 vial● In Stock | $49.99 | $4.999 |
Tracking since Apr 22, 2026 · 3 data points
Vendors Selling ARA-290
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View AllBPC-157/TB-500 Blend
RecoveryPreclinicalCombined healing peptide blend.
Bronchogen
RecoveryPreclinicalBronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
CAG
RecoveryPreclinicalCAG (often referring to a collagen-derived or cartilage-targeting peptide sequence) is a short research peptide studied for connective tissue and joint applications.
Cardiogen
RecoveryPreclinicalCardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
Cartalax
RecoveryPreclinicalCartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St.
Chonluten
RecoveryPreclinicalChonluten is a bioregulator preparation originating from Vladimir Khavinson's St.
View Full Dosage Guide →
Protocols, calculator & safety for ARA-290
Research Score
52 PubMed studies
Quality Indicators
Data Completeness
100%Research Credibility
Well-researched compound
Quick Facts
Molecular Weight
1397.64 g/mol
CAS Number
1002360-15-1
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What makes ARA-290 different from erythropoietin (EPO)?
ARA-290 was specifically engineered to separate the tissue-protective effects of EPO from its hematopoietic (red blood cell-stimulating) effects. Full-length recombinant EPO activates both the classical EPO receptor (driving red blood cell production) and the innate repair receptor or IRR (driving tissue protection and anti-inflammatory effects). This means EPO's tissue-protective benefits come with risks of polycythemia, hypertension, and thrombosis. ARA-290 is an 11-amino-acid peptide derived from a specific region of EPO (helix B surface) that binds the IRR selectively — producing the tissue-protective effects without activating the hematopoietic receptor (Brines et al., 2008). Clinical trials have confirmed this selectivity: ARA-290 does NOT increase hematocrit, does NOT raise blood pressure, and does NOT produce thrombotic events — validating the engineering goal. This makes ARA-290 a potentially safer way to access tissue-protective biology in contexts where EPO's hematopoietic effects would be unwelcome (neuropathic pain, tissue injury, chronic inflammation).
Does ARA-290 really work for small fiber neuropathy?
Yes, based on Phase 2 clinical trials — particularly for sarcoidosis-associated small fiber neuropathy. The SARD-2 trial (2017) was a randomized, double-blind, placebo-controlled Phase 2b study of 44 patients with sarcoidosis-SFN, comparing ARA-290 4 mg SubQ daily for 28 days to placebo. Results showed significant improvements in pain scores, neuropathy-specific symptom scales (SFNSL), autonomic symptom scores, and quality of life measures (Culver et al., 2017). Earlier Phase 2 studies showed similar results. For diabetic neuropathy, evidence is also positive but more preliminary. The mechanism is thought to involve reduced nerve-level inflammation, supported nerve fiber regeneration (documented as increased intraepidermal nerve fiber density on skin biopsy), and improved microvascular perfusion to nerves. This is one of the stronger evidence bases among research peptides — multiple published Phase 2 trials with consistent results. However, ARA-290 is NOT FDA-approved, so 'really work' needs to be understood in the context of investigational status. For sarcoidosis-SFN patients who have failed conventional therapy, it's a defensible consideration; ideally as part of a clinical trial or under specialist care.
How quickly does ARA-290 work?
Effects develop gradually, not acutely. You will NOT notice anything during the first week or two of treatment. In clinical trials, significant improvements over placebo became evident around week 2-4 of daily dosing. Peak response in sarcoidosis-SFN trials was typically around 4-8 weeks, with continued improvement through 12 weeks of treatment in follow-up studies. The gradual onset is consistent with the mechanism — ARA-290 acts through tissue-level anti-inflammatory effects, supports nerve fiber regeneration, and modulates cellular signaling. These processes take time. If you're evaluating whether ARA-290 is working for you, give it at least 4-6 weeks at 4 mg SubQ daily before concluding. Some users don't see peak benefit until 2-3 months. Unlike stimulants or GLP-1 agonists that produce immediate subjective effects, ARA-290 works through gradual biological modification. Realistic timeline expectations: noticeable improvement at 2-4 weeks (if you're a responder), peak effect at 6-12 weeks, sustained benefit with continued dosing.
Is ARA-290 safe for long-term use?
Short-term safety (up to 6 months in trials) has been excellent — no thrombotic events, no hypertension, no polycythemia, mild injection site reactions as the main adverse effect. Long-term safety data beyond 6-12 months are limited. Community use extends to multiple years in some cases, but rigorous safety follow-up at this duration has not been published. The engineering rationale (IRR selectivity without hematopoietic effects) suggests that the major concerning EPO-related risks should not occur, and trial data have validated this. That said, theoretical long-term concerns include: (1) potential subtle effects on immune surveillance, (2) unknown effects on cellular regeneration pathways over years of activation, (3) injection site lipodystrophy or scarring with prolonged daily use, (4) cost sustainability for prolonged treatment. Practical approach for long-term use: consider planned 'drug holidays' (1 month off after 3-6 months of daily use), monitor for any unexpected effects, maintain meaningful monitoring, and re-evaluate continued benefit periodically. If you're achieving sustained clinical benefit with no adverse effects, continuation at standard dose is reasonable — but indefinite use without re-evaluation is not advisable with any investigational compound.
Can ARA-290 cause cancer or affect tumor growth?
This is a theoretical concern that has been specifically considered in ARA-290 development. Classical EPO has raised concerns in oncology contexts because it has tissue-protective effects that could theoretically support tumor cell survival. Trials of recombinant EPO in some cancer populations have shown safety signals, leading to restrictive labeling. ARA-290's IRR selectivity may reduce this concern — the classical EPO receptor (the one driving hematopoietic effects and potentially concerning for tumor cells) is not activated by ARA-290. However, the IRR mechanism itself involves anti-apoptotic signaling that could theoretically affect tumor cells expressing IRR components. Clinical trials have not shown increased malignancy rates with ARA-290, but trial populations have been limited in size. The practical recommendation: patients with active malignancy or recent (<5 year) cancer history should not use ARA-290 without explicit oncology coordination. For patients in remission longer than 5 years without current malignancy concerns, use in appropriate indication (sarcoidosis-SFN, diabetic neuropathy) appears reasonable but with enhanced monitoring. This is an area where community practice has outpaced definitive safety data, and caution is appropriate.
Where can I get ARA-290 and how much does it cost?
ARA-290 (cibinetide) is an investigational compound not FDA-approved for any indication in the United States. Legal access options are limited: (1) Clinical trial participation — check clinicaltrials.gov for active ARA-290 trials in your area and condition, (2) Research peptide suppliers — compound available as 'research chemical' with valid Certificate of Analysis, (3) International pharmacy channels — varies by country regulation, (4) Specialized integrative medicine practices — some physicians may compound or prescribe through compounding pharmacies. Approximate 2026 US costs from research peptide suppliers: 16 mg vial $150-300+. At 4 mg daily (clinical trial dose), one vial lasts 4 days, translating to monthly cost of $1,200-2,400+. Some users report lower costs with alternative sourcing or dosing strategies. Quality varies significantly between suppliers — verify COA (≥98% HPLC purity, correct molecular weight 1257 Da), check vendor reputation, compare to clinical trial-grade material specifications. Avoid suspiciously cheap products — likely under-dosed or adulterated. Budget this compound carefully; it's among the most expensive peptide interventions. For clinical indications, clinical trial enrollment when available is often the best route (reliable product, clinical oversight, often free).
How does ARA-290 compare to BPC-157 and TB-500 for healing?
They work through different mechanisms and are potentially complementary. BPC-157 is a 15-amino-acid peptide that promotes tissue repair through growth hormone receptor effects, nitric oxide signaling, angiogenesis, and direct epithelial effects. Evidence base is largest in gastrointestinal healing and soft tissue injury. TB-500 is a fragment of Thymosin Beta-4 that promotes cell migration, actin sequestration, and matrix remodeling. Evidence base includes tendon/ligament repair and cardiac recovery. ARA-290 activates the innate repair receptor (IRR) with anti-inflammatory, anti-apoptotic, and tissue-protective signaling. Evidence base is strongest in neuropathic pain and small fiber neuropathy. The three peptides address different arms of tissue repair: BPC-157 for epithelial/GI and angiogenic effects, TB-500 for migration and matrix remodeling, ARA-290 for inflammation reduction and cellular protection. In community practice, they are commonly stacked — particularly for complex injury recovery — with the mechanistic logic being addressing multiple repair pathways simultaneously. Evidence for combined use is mechanism-based, not clinical-trial-supported. For specific indications: BPC-157 for gut and soft tissue injury, TB-500 for connective tissue and cardiac, ARA-290 for neuropathic and inflammatory conditions. For complex cases, the stack approach has theoretical appeal.
Will ARA-290 help with my diabetes complications?
Potentially for neuropathic complications, with more limited evidence for other diabetes-related issues. The strongest evidence is for diabetic neuropathy — multiple Phase 2 trials have shown improvements in neuropathic pain, nerve fiber density, and microvascular function in diabetic patients with painful peripheral neuropathy. If you have painful diabetic neuropathy that has failed conventional therapy (gabapentin, pregabalin, duloxetine), ARA-290 is a defensible consideration under specialist care. For other diabetes complications: microvascular dysfunction in general may respond (similar mechanism), but clinical evidence is more preliminary. Diabetic retinopathy has preclinical evidence; limited clinical data. Diabetic nephropathy has preclinical evidence; limited clinical data. Importantly, ARA-290 is NOT a substitute for glycemic control — the foundation of preventing and managing diabetes complications remains blood sugar optimization through diet, exercise, medications (metformin, SGLT2 inhibitors, GLP-1 agonists), and in some cases insulin. ARA-290 is best considered as adjunct therapy for specific complications, not as a primary diabetes treatment. A reasonable approach for diabetic neuropathy: optimize glycemic control + standard neuropathic pain management + ARA-290 4 mg SubQ daily + ALCAR 2-3 g + alpha-lipoic acid 600 mg BID + appropriate B12 and benfotiamine. Work with endocrinology and neurology for comprehensive management.
Do I need a prescription for ARA-290?
ARA-290 (cibinetide) is NOT an FDA-approved medication in the United States, so there is no FDA-approved prescribing label. That said, legitimate access generally requires some form of medical guidance: (1) Clinical trial enrollment — the most regulated access, with proper oversight and often no cost, (2) Compounding pharmacy prescription — some physicians (particularly integrative medicine, pain specialists) can write prescriptions for compounded ARA-290 from licensed compounding pharmacies, though this varies by jurisdiction, (3) Research peptide purchase — available without prescription in most jurisdictions as 'research chemical' with the legal caveat that it's not for human use (though community use obviously occurs). In countries where ARA-290 is approved or being pursued for approval, prescription requirements vary. Ethical considerations: for a serious condition like sarcoidosis-SFN or severe diabetic neuropathy, working with a knowledgeable physician is advisable regardless of legal minimums — you benefit from proper monitoring, dose optimization, interaction checking, and clinical support. For research peptide community use, the quality of sourcing and the validity of the indication matter more than strict prescription status. The practical recommendation: if possible, work with a physician familiar with ARA-290 (integrative medicine, specialized neurology, pain medicine). Look for a clinical trial in your area. If those aren't accessible, research peptide purchase with proper COA verification is the fallback, with understanding that you're operating without standard clinical oversight.
What's the main reason ARA-290 hasn't been FDA-approved yet?
ARA-290 (cibinetide) has received Orphan Drug Designation and Fast Track Designation for sarcoidosis-associated small fiber neuropathy, reflecting regulatory recognition of medical need. The main reasons it hasn't progressed to full approval include: (1) Clinical development complexity — moving from Phase 2 to Phase 3 in neuropathic pain indications is challenging, requires large trials, and the small fiber neuropathy patient population is relatively small, (2) The regulatory pathway for investigational peptides can be slow, (3) Araim Pharmaceuticals (the developer) has had to navigate commercial and funding realities of developing a drug for relatively specialized indications, (4) Regulatory agencies require comprehensive Phase 3 data on efficacy and safety for approval, which takes years and substantial investment, (5) The research community has also explored ARA-290 in other indications (diabetic complications, cardiovascular protection, etc.), but these have been earlier-stage research. The favorable clinical trial results for sarcoidosis-SFN — consistent improvements in pain, function, and quality of life, with excellent safety — would seem to support advancement, but the commercial and logistical challenges of developing a drug for a specialized indication have slowed progress. This situation (promising investigational compound with Phase 2 evidence but delayed or stalled regulatory approval) is unfortunately common. For patients seeking access, clinical trial participation is typically the best-supported route; community use through research peptide channels occurs but with all the caveats of investigational status.
Research Tools
Related Compounds
View AllBPC-157/TB-500 Blend
RecoveryPreclinicalCombined healing peptide blend.
Bronchogen
RecoveryPreclinicalBronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
CAG
RecoveryPreclinicalCAG (often referring to a collagen-derived or cartilage-targeting peptide sequence) is a short research peptide studied for connective tissue and joint applications.
Cardiogen
RecoveryPreclinicalCardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
Cartalax
RecoveryPreclinicalCartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St.
Chonluten
RecoveryPreclinicalChonluten is a bioregulator preparation originating from Vladimir Khavinson's St.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.